Search results

Order by most recent / most popular / relevance

Results: 1-4 of 4

Canada’s Federal Court of Appeal limits damages available to delayed generics

Torys LLP
-
Canada
-
June 8 2009

On June 4, 2009, in Merck Frosst Canada Inc. v. Apotex, Inc., the Federal Court of Appeal released an important decision limiting the range of damages available in actions under section 8 of the Patented Medicines (Notice of Compliance) Regulations

Supreme Court of Canada rules on data protection for drug innovators

Torys LLP
-
Canada
-
February 8 2012

On February 3, 2012, the Supreme Court of Canada released its long-awaited decision in Merck Frosst Canada Ltd. v. Canada (Health), the culmination of over a decade of litigation between Merck and the Minister of Health

Health Canada announces intent to develop a framework for orphan drug approval

Torys LLP
-
Canada, USA
-
October 5 2012

On October 3, 2012, Health Canada issued a press release announcing that it will develop a framework for the marketing approval of drugs to treat rare life-threatening, seriously debilitating or serious chronic rare diseases that are commonly referred to as "orphan drugs."

Court affirms Health Canada’s broad discretion in review of drug submissions

Torys LLP
-
Canada
-
April 13 2010

In a recent decision of the Federal Court in Hospira Healthcare Corporation v. Canada (Attorney General) the Court affirmed that Health Canada has broad discretion in interpreting the Food and Drug Regulations to determine the content of an application for the marketing approval of a drug

Search results

Canada’s Federal Court of Appeal limits damages available to delayed generics

Supreme Court of Canada rules on data protection for drug innovators

Health Canada announces intent to develop a framework for orphan drug approval

Court affirms Health Canada’s broad discretion in review of drug submissions

Current Search

Suggested Facets

Author

Workarea